Vimarsana
Biggest News Aggregation in the World

Ensign Professor News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Ensign Professor. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Ensign Professor Today - Breaking & Trending Today

Research cores: Making science easier, more fruitful, and more efficient - Vimarsana News

Research cores: Making science easier, more fruitful, and more efficient

Yale’s research cores enable scientists across campus to interact, collaborate, and develop new applications that advance the university’s scientific mission.

Source: yale.edu
Research cores make science easier, more fruitful, and more efficient - Vimarsana News

Research cores make science easier, more fruitful, and more efficient

Yale’s research cores enable scientists across campus to interact, collaborate, and develop new applications that advance the university’s scientific mission.

Source: yale.edu
Lung-MAP: A beacon of hope for lung cancer patients - Vimarsana News

Lung-MAP: A beacon of hope for lung cancer patients

The unique public-private partnership that for almost a decade has undergirded the first National Cancer Institute (NCI)-sponsored precision medicine clinical trial in lung cancer can serve as a model for future clinical research that is more rapid, innovative, and inclusive.

A Phase 2 Study of Anti-Siglec-15 Antibody, NC318, in Combination with Pembrolizumab (NCT04699123) Demonstrates Clinical Activity in Patients with Advanced PD-1 Axis Inhibitor Refractory NSCLC - Vimarsana News

A Phase 2 Study of Anti-Siglec-15 Antibody, NC318, in Combination with Pembrolizumab (NCT04699123) Demonstrates Clinical Activity in Patients with Advanced PD-1 Axis Inhibitor Refractory NSCLC

• Data presented at the 2023 World Conference on Lung Cancer hosted by the International Association for the Study of Lung Cancer in Singapore BELTSVILLE, Md., Sept. 12, 2023 -- NextCure,...

Dr Herbst on Adjuvant Osimertinib in EGFR-mutant NSCLC - Vimarsana News

Dr Herbst on Adjuvant Osimertinib in EGFR-mutant NSCLC

Roy S. Herbst, MD, PhD, discusses findings from the overall survival analysis of the phase 3 ADAURA trial of adjuvant osimertinib in patients with stage IB to IIIA resected non–small cell lung cancer harboring EGFR mutations.